Future head-to-head studies comparing the two agents or including recent potent GLP1RAs and GLP1/GIP co-agonists, to expand on the present observations, and thereby enhance tailored therapeutic approaches for managing type 2 diabetes are warranted. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.